The Asymptomatic Carotid Artery Progression Study (ACAPS) compared the usefulness of lovastatin alone or in combination with warfarin in the prevention of 3-year progression of mean maximum intimal-medial thickness (IMT), which is a measure of early atherosclerosis. The factorally designed, placebo-controlled study enrolled 919 men and women aged 40–79 who had moderately elevated low-density-lipoprotein (LDL) cholesterol and a single maximum IMT of 1.5–3.5 mm in the carotid arteries. Lovastatin significantly reduced LDL cholesterol. The mean maximum IMT declined at an annual rate of 0.009 mm among those persons taking lovastatin while the mean maximum IMT increased by 0.006 mm in the controls (p = 0.001). In addition, deaths and the combined frequency of coronary deaths, nonfatal myocardial infarctions and strokes were significantly lowered among the lovastatin-treated groups. Only 5 strokes (3 hemorrhages) were detected in the study; all occurred among those persons who were receiving lovastatin placebo. Our study suggests that early administration of lipid-lowering drugs halts the progression of early atherosclerosis in the carotid artery. In turn, such early primary preventive treatment may lessen the risk of important ischemic vascular events including stroke.

Keywords:
Lovastatin, Intimal-medial thickness, Atherosclerosis, Hyperlipidemia, Carotid artery
This content is only available via PDF.
© 1995 S. Karger AG, Basel
1995
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.